Service finalizes and issues a Prospectus soliciting offers to provide these services under a new longer-term contract. This short-term extension will be for a one-year period beginning November 1, 2000. This notice is in pursuant to 36 CFR part 51, section 51.23.

SUPPLEMENTARY INFORMATION: The concession contract at Crater Lake National Park will expire on October 31, 2000. The National Park Service is in the process of completing the necessary documents to competitively award a new longer-term concession contract. This 1-year extension is necessary to allow for completion and issuance of the Prospectus, leading to the selection of a concessioner for a new longer-term concession contract.

Information about this notice can be sought from: National Park Service, Chief, Concession Program Management Office, Pacific West Region, Attn: Mr. Tony Sisto, 600 Harrison Street, Suite 600, San Francisco, California 94107–1372 or call (415) 427–1366.

Dated: September 14, 2000.

Cynthia Ip,

Acting Regional Director, Pacific West Region.

[FR Doc. 00–24501 Filed 9–22–00; 8:45 am]

BILLING CODE 4310–70–P

DEPARTMENT OF THE INTERIOR

National Park Service

Pipestone National Monument; Environmental Impact Statement

AGENCY: National Park Service, Interior.

ACTION: Notice of intent to prepare a general management plan and environmental impact statement for Pipestone National Monument, Minnesota.

SUMMARY: The National Park Service (NPS) will prepare a general management plan (GMP) and an associated environmental impact statement (EIS) for Pipestone National Monument, Minnesota, in accordance with section 102(2)(C) of the National Environmental Policy Act of 1969 (NEPA). This notice is being furnished as required by NEPA Regulations 40 CFR 1501.7.

To facilitate sound planning and environmental assessment, the NPS intends to gather information necessary for the preparation of the EIS, and to obtain suggestions and information from other agencies and the public on the scope of issues to be addressed in the EIS. Comments and participation in this scoping process are invited.

Participation in the planning process will be encouraged and facilitated by various means, including newsletters and open houses or meetings. The NPS will conduct public scoping meetings to explain the planning process and to solicit opinion about issues to address in the GMP/EIS. Notification of all such meetings will be announced in the local press and in NPS newsletters.

ADDRESSES: Written comments and information concerning the scope of the EIS, requests to be added to the project mailing list, and other matters should be directed to: Mr. Jim LaRock, Superintendent, Pipestone National Monument, 36 Reservation Avenue, Pipestone, Minnesota 56164. Telephone: 507–825–5464. E-mail: jim_larock@nps.gov

FOR FURTHER INFORMATION CONTACT: Jim LaRock, Superintendent, Pipestone National Monument, at the address and telephone number listed above.

SUPPLEMENTARY INFORMATION: Pipestone National Monument is located near the Minnesota-South Dakota border. Within the 283-acres monument are pipestone (catlinite) quarries, native tallgrass prairie, and quartzite bluffs. The monument was established for two purposes: (1) To manage the pipestone quarries to provide American Indians the opportunity to quarry the pipestone, and (2) to preserve and manage the ethnological, historical, archeological, and geological resources of the area for the betterment and enjoyment of all.

In accordance with NPS Park Planning policy, the GMP will ensure the monument has a clearly defined direction for resource preservation and visitor use. The GMP will help define what types of resource conditions, visitor uses, and management actions will best achieve the mission of the NPS and Pipestone National Monument. Additionally the GMP process will address facility needs, staffing, park interpretation and activities, and maintenance. It will be developed in consultation with servicewide program managers, interested parties, and the general public. It will be based on an adequate analysis of existing and potential resource conditions and visitor experiences, environmental impacts, and costs of alternative courses of action.

The environmental review of the GMP/EIS for the monument will be conducted in accordance with requirements of the NEPA (42 U.S.C. 4371 *et seq.*), NEPA regulations (40 CFR 1500–1508), other appropriate Federal regulations, and NPS procedures and policies for compliance with those regulations.

Dated: September 13, 2000.

Linda C. Witkowski,

Acting Regional Director.

[FR Doc. 00–24502 Filed 9–22–00; 8:45 am]

BILLING CODE 4310–70–P

DEPARTMENT OF THE INTERIOR

National Park Service

Death Valley National Park Advisory Commission; Notice of Meeting

Notice is hereby given in accordance with the Federal Advisory Commission Act that a meeting of the Death Valley National Park Advisory Commission will be held October 11 and 12, 2000 at the Furnace Creek Inn within Death Valley National Park.

The main agenda will include:

- Death Valley National Park's Revised Draft General Management Plan;
- Updates on Park Operational Plans;
- Appropriate field trips within Death Valley National Park, if time allows.

The Advisory Commission was established by PL #03–433 to provide for the advice on development and implementation of the General Management Plan.

Members of the Commission are Janice Allen, Kathy Davis, Michael Dorame, Mark Ellis, Pauline Esteves, Stanley Haye, Sue Hickman, Cal Jepson, Joan Lolmaugh, Gary O'Connor, Alan Peckham, Michael Prather, Wayne Schulz, and Gilbert Zimmerman.

This meeting is open to the public.

Richard H. Martin,

Superintendent, Death Valley National Park.

[FR Doc. 00–24500 Filed 9–22–00; 8:45 am]

BILLING CODE 4310–70–P

DEPARTMENT OF THE INTERIOR

National Park Service

AGENCY: National Park Service, Interior.

ACTION: Notice of Public Hearing; Mojave National Preserve.

SUMMARY: Pursuant to public comment to **Federal Register** Notice of Realty Action published April 18, 2000 (Volume 65, Number 75, pages 20831–20832) on the exchange of federal property for private property at Mojave National Preserve, this notice announces a public hearing to be held regarding the proposed exchange, at the date, time and place noted below. The hearing is open to the public.

Date: October 11, 2000.

Time: 11 am–2 pm.

Place: Hole in the Wall Visitors Center, Mojave National Preserve.

FOR FURTHER INFORMATION CONTACT: The Offices of the Mojave National Preserve, Barstow, California 92311. Tel. (760) 255–8801.

SUPPLEMENTARY INFORMATION: In order to resolve the encroachment of a private residence and ranch headquarters on federal land, it is necessary for the National Park Service to effect a land exchange at Mojave National Preserve, San Bernardino California. Comments received in response to the Federal Register Notice of Realty Action, included requests for a public hearing on the exchange. National Park Service staff will brief those in attendance at the hearing on the history, purpose, and procedures involved in the exchange. For more detailed information on the proposed exchange, see **Federal Register** Notice of Realty Action published April 18, 2000 (Volume 65, Number 75, pages 20831–20832).

Dated: September 12, 2000.

Cynthia L. Ip,

Acting Regional Director, Pacific West Region.

[FR Doc. 00–24503 Filed 9–22–00; 8:45 am]

BILLING CODE 4310–70–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances; Notice of Application

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(I)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Section 1301.34 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on June 19, 2000, Abbott Laboratories, 1776 North Centennial Drive, McPherson, Kansas 67460–1247, made application to the Drug Enforcement Administration to be registered as an importer of remifentanil (9739), a basic class of controlled substance listed in Schedule II.

The firm plans to import the remifentanil to manufacture Ultiva for the U.S. market.

Any manufacturer holding, or applying for, registration as a bulk manufacturer of this basic class of controlled substance may file written comments on or objections to the application described above and may, at the same time, file a written request for a hearing on such application in accordance with 21 CFR 1301.43 in such form as prescribed by 21 CFR 1316.47.

Any such comments, objections or requests for a hearing may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than October 25, 2000.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice at 40 FR 43745–46 (September 23, 1975), all applicants for registration to import a basic class of any controlled substance in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(a), (b), (c), (d), (e), and (f) are satisifed.

Dated: September 8, 2000.

John H. King,

Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 00–24556 Filed 9–22–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 24, 2000, American Radiolabeled Chemical, Inc., 11624 Bowling Green Drive, St. Louis, Missouri 63146, made application by renewal to the Drug Enforcement Administration (DEA) for registratin as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Gamma hydroxybutyric acid (2010).	I
Lysergic acid diethylamide (7315)	I
Dimethyltryptamine (7435)	I
Dihydromorphine (9145)	I
Phencyclidine (7471)	II
Cocaine (9041)	II
Codeine (9050)	II
Hydromorphone (9150)	II
Benzoylecgonine (9180)	II
Meperidine (9230)	II
Metazocine (9240)	II
Morphine (9300)	II
Oxymorphone (9652)	II

The firm plans to bulk manufacture small quantities of the listed controlled substances as radiolabeled compound.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than November 24, 2000.

Dated: September 6, 2000.

John H. King,

Deputy Assistant Administrator, Office of Diversion Control Drug Enforcement Administration.

[FR Doc. 00–24560 Filed 9–22–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances; Notice of Application

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Section 1301.34 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on July 5, 2000, Glaxo Wellcome Inc., Attn: Jeffrey A. Weiss, 1011 North Arendell Avenue, P.O. Box 1217, Zebulon, North Carolina 27597–2309, made application by renewal to the Drug Enforcement Administration to be registered as an importer of remifentanil (9739), a basic class of controlled substance listed in Schedule II.